Table 4.
Phase 3 clinical trial results of Covid-19 candidate vaccines.
| Vaccine | BNT162b2 | mRNA-1273 | AZD1222/ChAdOx1 | Ad26COV2S | CoronaVac | GamCOVIDVac/Sputnik V |
|---|---|---|---|---|---|---|
| Analysis | Final | Primary | Primary | Primary | Interim | Interim |
| Total participants | 43,548 | 30,420 | 17,178 | 39,321 | 12,607 | 21,977 |
| Vaccine group | 21,720 | 15,210 | 8597 | 19,630 | NA | 16,501 |
| Placebo group | 21,728 | 15,210 | 8581 | 19,691 | NA | 5476 |
| Efficacy assessment | 7 days after 2nd dose | 14 days after 2nd dose | 14 days after 2nd dose | 14 days after single dose | ≥15 days after 2nd dose | 21 days after 1st dose |
| Total confirmed cases | 170 | 196 | 332 | 464 | NA | 78 |
| Vaccine group | 8 | 11 | 84 | 116 | NA | 16 |
| Placebo group | 162 | 185 | 248 | 348 | NA | 62 |
| Severe cases (additional hospitalized cases) | ||||||
| Vaccine group | 1 | 0 | 108 (0) | 83 (2) | NA | 0 |
| Placebo group | 9 | 30 | 127 (15) | 96 (29) | NA | 20 |
| Deaths | ||||||
| Vaccine group | 0 | 0 | 2a | 3a | NA | 3a |
| Placebo group | 0 | 1 | 5a | 11a, 5b | NA | 1a |
| Efficacy overall | 95% | 94.1% | 66.7% | 66.9% | 50.4% | 91.6% |
a
Death was not Covid-19 related.
b
Death was Covid-19 related. NA, not available.